JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

about

Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

P2860

Q58786408-9174EC51-1915-4DDB-8C83-3E175A89577A

P2860

JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

Item

http://www.wikidata.org/entity/Q38701688

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

JUN-Mediated Downregulation of ...... EGFR-mutant NSCLC Cell Lines.

@en

type

Item

label

JUN-Mediated Downregulation of ...... EGFR-mutant NSCLC Cell Lines.

@en

prefLabel

JUN-Mediated Downregulation of ...... EGFR-mutant NSCLC Cell Lines.

@en

P1476

JUN-Mediated Downregulation of ...... EGFR-mutant NSCLC Cell Lines.

@en

P2093

Ah Young Joo

http://www.w3.org/2001/XMLSchema#string

Anthony L Nguyen

http://www.w3.org/2001/XMLSchema#string

Carolina Garri

http://www.w3.org/2001/XMLSchema#string

Damien M Wood

http://www.w3.org/2001/XMLSchema#string

David B Agus

http://www.w3.org/2001/XMLSchema#string

Janet Lee

http://www.w3.org/2001/XMLSchema#string

Jonathan E Katz

http://www.w3.org/2001/XMLSchema#string

Katrin Tiemann

http://www.w3.org/2001/XMLSchema#string

Lindsey D Hughes

http://www.w3.org/2001/XMLSchema#string

Parag Mallick

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Discovery of Potent and Selective Covalent Inhibitors of JNK

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

1645-1657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-16-0564

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kian Kani

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28566434

http://www.w3.org/2001/XMLSchema#string

P932

5558834

http://www.w3.org/2001/XMLSchema#string

JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

about

P2860

P2860

JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932